1h Free Analyst Time
According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.Speak directly to the analyst to clarify any post sales queries you may have.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.
The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
- A2A Pharmaceuticals Inc
- Alexion Pharmaceuticals Inc
- Alumis Inc
- Amgen Inc
- Atomwise Inc
- BeiGene Ltd
- Bristol-Myers Squibb Co
- Galapagos NV
- Haisco Pharmaceutical Group Co Ltd
- InnoCare Pharma Ltd
- Kinaset Therapeutics Inc
- Merck & Co Inc
- Neuron23 Inc
- Nimbus Therapeutics LLC
- Oncostellae SL
- Pfizer Inc
- Priovant Therapeutics Inc
- Sareum Holdings Plc
- Shenzhen Chipscreen Biosciences Co Ltd
- Simcere Pharmaceutical Group Ltd
- Sudo Biosciences Inc
- Technoderma Medicines Inc
- Theravance Biopharma Inc
- TLL Pharmaceutical LLC
- Ventyx Biosciences Inc
- Xilingyuan Pharmaceutical Co Ltd
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
- A2A-I-01 - Drug Profile
- Product Description
- Mechanism Of Action
- BGB-23339 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-986322 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- brepocitinib tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cerdulatinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CS-43001 - Drug Profile
- Product Description
- Mechanism Of Action
- deucravacitinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ESK-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FTP-637 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GLPG-3667 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ICP-332 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ICP-488 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KN-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NDI-031407 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NDI-034858 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Oral TYK2 (JH2) - Drug Profile
- Product Description
- Mechanism Of Action
- OST-122 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- QY-201 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SAR-20347 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SDC-1801 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SDC-1802 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit TYK2 for Inflammatory Disorders and Neuroinflammation - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit TYK2 for Unspecified Immunological Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SMP-117 - Drug Profile
- Product Description
- Mechanism Of Action
- TDM-180935 - Drug Profile
- Product Description
- Mechanism Of Action
- TDMSLE-01 - Drug Profile
- Product Description
- Mechanism Of Action
- TLL-018 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TYK2 (JH2) Program 2 - Drug Profile
- Product Description
- Mechanism Of Action
- TYK2 (JH2) Program 3 - Drug Profile
- Product Description
- Mechanism Of Action
- TYK2 (JH2) Program 4 - Drug Profile
- Product Description
- Mechanism Of Action
- VTX-958 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
- Featured News & Press Releases
- Nov 08, 2022: Sareum Holdings : Update on SDC-1801 CTA application
- Sep 28, 2022: Alumis announces initiation of patient dosing in phase 2 clinical trial of ESK-001 for the treatment of plaque psoriasis
- Sep 12, 2022: Bristol Myers Squibb announces new Sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis
- Sep 09, 2022: US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis
- Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
- Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
- Aug 11, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
- Aug 02, 2022: InnoCare announces first subject dosed in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China
- Jul 28, 2022: Sareum submits clinical trial authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an operational update
- Jun 28, 2022: Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral Brepocitinib in dermatomyositis and lupus
- Jun 01, 2022: Late-Breaking data at EULAR 2022 demonstrate deucravacitinib significantly improved disease activity in phase 2 PAISLEY study in Systemic Lupus Erythematosus
- Jun 01, 2022: Lupus Research Alliance and Lupus Therapeutics response to positive data from phase 2 study on potential first-in-class lupus treatment
- May 19, 2022: Nimbus Therapeutics presents additional clinical data from phase 1 studies of oral allosteric TYK2 inhibitor at SID Annual Meeting
- May 12, 2022: New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis
- Apr 11, 2022: European patent granted for Sareum's SDC-1802, a novel small molecule TYK2/JAK1 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by A2A Pharmaceuticals Inc, 2022
- Pipeline by Alexion Pharmaceuticals Inc, 2022
- Pipeline by Alumis Inc, 2022
- Pipeline by Amgen Inc, 2022
- Pipeline by Atomwise Inc, 2022
- Pipeline by BeiGene Ltd, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Galapagos NV, 2022
- Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
- Pipeline by InnoCare Pharma Ltd, 2022
- Pipeline by Kinaset Therapeutics Inc, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Neuron23 Inc, 2022
- Pipeline by Nimbus Therapeutics LLC, 2022
- Pipeline by Oncostellae SL, 2022
- Pipeline by Pfizer Inc, 2022
- Pipeline by Priovant Therapeutics Inc, 2022
- Pipeline by Sareum Holdings Plc, 2022
- Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Pipeline by Simcere Pharmaceutical Group Ltd, 2022
- Pipeline by Sudo Biosciences Inc, 2022
- Pipeline by Technoderma Medicines Inc, 2022
- Pipeline by Theravance Biopharma Inc, 2022
- Pipeline by TLL Pharmaceutical LLC, 2022
- Pipeline by Ventyx Biosciences Inc, 2022
- Pipeline by Xilingyuan Pharmaceutical Co Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A2A Pharmaceuticals Inc
- Alexion Pharmaceuticals Inc
- Alumis Inc
- Amgen Inc
- Atomwise Inc
- BeiGene Ltd
- Bristol-Myers Squibb Co
- Galapagos NV
- Haisco Pharmaceutical Group Co Ltd
- InnoCare Pharma Ltd
- Kinaset Therapeutics Inc
- Merck & Co Inc
- Neuron23 Inc
- Nimbus Therapeutics LLC
- Oncostellae SL
- Pfizer Inc
- Priovant Therapeutics Inc
- Sareum Holdings Plc
- Shenzhen Chipscreen Biosciences Co Ltd
- Simcere Pharmaceutical Group Ltd
- Sudo Biosciences Inc
- Technoderma Medicines Inc
- Theravance Biopharma Inc
- TLL Pharmaceutical LLC
- Ventyx Biosciences Inc
- Xilingyuan Pharmaceutical Co Ltd
